• 検索結果がありません。

Reactivation of Hepatitis B Virus in Patients With Undetectable HBsAg Undergoing Chemotherapy for Malignant Lymphoma or Multiple Myeloma<Abstract of dissertation>

N/A
N/A
Protected

Academic year: 2021

シェア "Reactivation of Hepatitis B Virus in Patients With Undetectable HBsAg Undergoing Chemotherapy for Malignant Lymphoma or Multiple Myeloma<Abstract of dissertation>"

Copied!
2
0
0

読み込み中.... (全文を見る)

全文

(1)

Nagoya City University Academic Repository

学 位 の 種 類

博士 (医学)

報 告 番 号

甲第1555号

学 位 記 番 号 第1110号

氏 名

松居 剛志

授 与 年 月 日

平成 29 年 3 月 24 日

学位論文の題名

Reactivation of Hepatitis B Virus in Patients With Undetectable

HBsAg Undergoing Chemotherapy for Malignant Lymphoma or Multiple

Myeloma

(悪性リンパ腫、多発性骨髄腫に対する化学療法施行の HBs 抗原陰性患者

における HBV 再活性化対策)

Journal of Medical Virology Vol.85:P1900–1906, 2013

論文審査担当者

主査: 飯田 真介

(2)

Reactivation of Hepatitis B Virus in Patients With Undetectable HBsAg

Undergoing Chemotherapy for Malignant Lymphoma or Multiple Myeloma

Reactivation of the hepatitis B virus (HBV) is a well-recognized complication following systemic chemotherapy for hematological malignancies. However, the incidence or risk factors of HBV

reactivation remain unclear because only a few prospective cohorts have presented for this new clinical entity. The aim of this study was to clarify the frequency and risk factors of HBV reactivation in

hepatitis B surface antigen (HBsAg) undetectable patients with malignant lymphoma or multiple myeloma, during or after chemotherapy. A total of 109 patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma were enrolled in this study. Anti-hepatitis B surface (anti-HBs) and anti-hepatitis B core (anti-HBc) were checked before treatment, and HBV DNA in sera was quantified monthly during and after chemotherapy. Out of 109 patients, 42 (38.5%) had anti-HBs and 59 (54.1%) had anti-HBc. Among the 59 anti-HBc positive patients, four patients (4/59, 6.8%) showed HBV reactivation during 20.5 median follow-up months. In all four patients with HBV reactivation, peripheral lymphocyte counts before chemotherapy were lower than those without HBV reactivation (P . 0.033). HBV reactivation occurred during and after chemotherapy containing rituximab for non-Hodgkin lymphoma. Four patients, who had HBV reactivation, did not develop de novo hepatitis due to HBV reactivation and were able to undergo chemotherapy against malignant lymphoma as scheduled. Monitoring of HBV DNA in sera is useful for the early diagnosis of HBV reactivation, and preemptive therapy is an useful

alternative to prevent hepatitis due to HBV reactivation. Patients must be monitored periodically for HBV-DNA levels during and after chemotherapy.

参照

関連したドキュメント

After washing out the input virus, cells were cultured in normal medium for the first 8 days and then cultured with IL-1 ␤ , IFN ␣ , or lamivudine for the following 4

Three days after transfection, cccDNA from nuclear Hirt-extracted DNAs was amplified by RCA and digested with EcoRI to cleave the concatemer into monomers of

Kaplan – Meier plot of overall survival after hepatic arterial infusion chemotherapy commenced, according to Child – Pugh class and Child–Pugh score.. The mean Child – Pugh scores

Prichett reported that lengthening of the ulna and correction of the radius, particularly with the use of an external fixator, has given predictable results and is a useful method

[r]

Ability of HBx to overcome H-RAS V12 -induced senescence in BJ cells immortalized by hTERT Seeing as HBx did not exhibit the ability to immortalize primary human fibroblasts or

RNA polymerase II subunit 5 (RPB5) is part of the lower jaw of RNAPII , and the exposed domain of RPB5 serves in interactions with transcriptional regulators including Hepatitis B

[Journal Article] Two independent regions of human telomerase reverse transcriptase (hTERT) are important for their oligomerization and telomerase 2002.